Spiral Genetics, a Seattle, Wa.-based big data bioinformatics company, closed its $3m Series A financing.
The round was led by venture capital firm DFJ.
The company intends to use the funds to expand its bioinformatics engineering team, scale its sales and marketing efforts and accelerate product development.
Led by Adina Mangubat, CEO, Spiral Genetics provides a cloud-based bioinformatics analysis platform which allows researchers to analyze a whole human genome from raw DNA sequence data to a fully annotated list of genetic variants in just 3 hours. It is used by customers across a variety of industries including drug development and agriculture.
In addition to the funding, Spiral announced its partnership with Omicia, a San Francisco Bay Area-based developer of scalable and fully integrated informatics systems specifically designed to interpret human genome sequences for research and clinical applications. The partnership leverages Omicia’s Opal solution which is a variant analysis tool that empowers researchers and clinicians to analyze genomes and prioritize disease-causing variants.